Table 1. Demographics and baseline characteristics of patients with CRC with PM.

Variable	OX-HIPEC, n=61	OX-HIPEC + 5-FU EPIC, n=24	OXIRI- HIPEC, n=48	Whole cohort, n=133	P value
Age [years], median [IQR]	58 [46–67]	58 [50–64]	59 [46–65]	59 [47–65]	NS
Gender, n [%]					0.057
Male	25 [41]	6 [25]	26 [54]	57 [43]
Female	36 [59]	18 [75]	22 [46]	76 [57]
Primary tumor, n [%]					0.75
Colon	55 [90]	23 [96]	45 [94]	123 [92]
Rectum	6 [10]	1 [4]	3 [6]	10 [8]
PM disease, n [%]					0.26
Synchronous	34 [56]	14 [58]	34 [71]	82 [62]
Metachronous	27 [44]	10 [42]	14 [29]	51 [38]
Neoadjuvant treatment, n [%]	24 [39]	16 [67]	39 [81]	79 [59]	0.0004
Node positive primary, n [%]	46 [75]	12 [50]	34 [49]	92 [69]	0.003
Missing data	1 [2]	6 [25]	2 [4]	9 [7]
Differentiation, n [%]					0.3
Poor	18 [30]	8 [33]	11 [23]	37 [28]
Moderate/high	40 [66]	11 [46]	34 [71]	85 [64]
Missing data	3 [4]	5 [21]	3 [6]	11 [8]
Signet cells, n [%]	8 [13]	3 [12]	6 [12]	17 [13]	1.00
PCI, median [IQR]	14 [9–23]	17 [11–24]	13 [7–20]	14 [7–22]	NS
Liver metastases, n [%]	4 [7]	6 [25]	6 [13]	35 [16]	0.06
Operating time, mean ± SD	456±197	542±155	522±137	495±132	0.047
CC score, n [%]					0.094
0	55 [90]	19 [79]	44 [92]	118 [89]
1	5 [8]	1 [4]	3 [6]	9 [7]
2	0 [0]	3 [13]	1 [2]	4 [3]
3	1 [2]	1 [4]	0 [0]	2 [1]
Adjuvant chemotherapy, n [%]					0.64
Yes	26 [43]	11 [46]	15 [31]	75 [56]
No	30 [49]	13 [54]	32 [67]	52 [39]
Missing data	5 [8]	0 [0]	1 [2]	6 [5]

CRC, colorectal cancer; PM, peritoneal metastases; HIPEC, hyperthermic intraperitoneal chemotherapy; OX-HIPEC, oxaliplatin-based HIPEC; 5-FU, 5-fluorouracil; EPIC, post-operative intraperitoneal chemotherapy; OXIRI-HIPEC, oxaliplatin-irinotecan-based HIPEC; PCI, peritoneal cancer index; CC, completeness of cytoreduction.